Global mental disorder treatment market to exceed $ 75.7 billion by 2027, according to Coherent Market Insights (CMI)


SEATTLE – (COMMERCIAL THREAD) – According to Coherent Market Insights, the global mental disorder treatment market is estimated at 48.4 billion US dollars in 2020 and is expected to post a CAGR of 6.6% during the forecast period (2020-2027).

Key trends and analysis:

Key Companies Focus on Regulatory Body Product Approvals to Develop Treatment for Mental Disorders is Expected to Drive Global Market Growth mental disorder treatment market during the forecast period. For example, in April 2019, Lupine Limited received approval from the United States Food and Drug Administration (FDA) for its Fluoxetine United States Pharmacopeia (USP) tablets in a strength of 60 mg for the treatment of depression in adults.

Among the regions, North America is expected to hold a dominant position in the global mental disorder treatment market during the forecast period, with key players focusing on strategic alliance with governments of various low income such as Africa to improve mental health care. For example, in 2019, Johnson & Johnson Services Inc. (Johnson & Johnson) announced its strategic partnership with the government of Rwanda to strengthen and significantly expand access to quality treatment for mental disorders in the country.

Detailed Study Report Buy Now @ https://www.coherentmarketinsights.com/insight/buy-now/4326

Key points of the market:

The global mental disorder treatment market is expected to show a 6.6% CAGR during the forecast period, due to the increasing prevalence of mental disorders around the world. For example, according to the World Health Organization report published in 2019, indicated that approximately 45 million people suffered from bipolar mental disorder worldwide in 2019.

Competitive landscape:

Major players operating in the global mental disorder treatment market include Allergan plc. Eli Lilly and Company, VistaGen Therapeutics, Sanofi SA, Novartis International AG, Mylan NV, Amneal Pharmaceuticals LLC, Cipla Ltd, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Lupine Limited, Janssen Pharmaceutica, Bristol Myers Squibb and Sumitomo Dainippon Pharma Co. , Ltd.

Request a copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/4326

Market segmentation :

  • Global Mental Disorder Treatment Market, By Disorder Type:
    • Depression

    • Bipolar disorder

    • Schizophrenia

    • Dementia

    • Post-traumatic stress disorder

    • Others

  • Global Mental Disorder Treatment Market, By Drug:
    • Anti-depressants

    • Anti stress

    • Mood stabilizing drug

    • Antipsychotic drugs

  • Global Mental Disorder Treatment Market, By Distribution Channel:
    • Hospital pharmacies

    • Retail pharmacies

    • Online pharmacies

  • Global Mental Disorder Treatment Market, By Region:
    • North America

    • Latin America

      • By country:

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By country:

        • Germany

        • UK

        • France

        • Italy

        • Spain

        • Russia

        • The rest of europe

    • Asia Pacific

      • By country:

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia-Pacific

    • Middle East

      • By country / region:

        • CCG

        • Israel

        • Rest of the Middle East

    • Africa

      • By country / region:

        • South Africa

        • central Africa

        • North Africa

Related Market Intelligence Report:

Mental health software market, by mode of deployment (on-premise and subscription (cloud-based)), by mode of access (desktops / laptops and tablets / smartphones), by function (telehealth, payroll, management Revenue Cycle (RCM), General Ledger, Business Intelligence, Electronic Health Record (EHR) and Clinical Decision Support), by application (commercial, hospitals and clinics, others (psychiatrists, social workers, psychologists, counselors , Nurse Practitioners, Group Therapists) and Residential) and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) – Size, Share, Outlook and Opportunity Analysis, 2019 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/mental-health-software-market-3605

Depression therapy market, drug type (antidepressants (selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), serotonin modulators), tricyclic and tetracyclic antidepressants and atypical antidepressants) , antipsychotics and others), by indication (major depressive disorder (MDD)), bipolar disorder, dysthymic disorder, postpartum depression, seasonal affective disorder (SAD), premenstrual dysphoric disorder (PMDD) and others), by distribution channel ( Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) – Size, Share, Trends and Forecast 2018 – 2026

Read more: https://www.coherentmarketinsights.com/market-insight/depression-therapeutics-market-1307

About Us:

Consistent market information is a global market intelligence and consulting organization that aims to help our plethora of clients achieve transformational growth by helping them make critical business decisions. Our head office is located in India, we have a sales office in the world financial capital in the United States, and sales consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 57 countries around the world.


Comments are closed.